Skip to main content
. 2022 Sep 1;39(4):645–650. doi: 10.5114/ada.2022.118919

Figure 2.

Figure 2

Mechanism of action for proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies. Monoclonal antibodies against PCSK9 (red) block binding of PCSK9 (brown) to the low-density lipoprotein receptor (LDL-R) (green) and prevent LDL-R degradation, which results in a higher LDL receptor recycling and reduced serum LDL level